| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| William Victor Bobo, Stefania Bonaccorso, Karuna Jayathilake, Herbert Yale Meltze. Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder. Psychiatry research. vol 189. issue 2. 2011-11-08. PMID:21802150. |
baseline body mass index (bmi), baseline bmi status (normal, overweight, obese) and early (1 month) bmi increases were tested as predictors of 6- and 12-month increases in glucose and lipid measures in 82 olanzapine (olz)- and 78 risperidone (ris)-treated patients with schizophrenia, schizoaffective disorder, or bipolar disorder who participated in a 12-month randomized, prospective metabolic effects study. |
2011-11-08 |
2023-08-12 |
Not clear |
| Joseph F Cubell. A head-to-head comparison of risperidone and divalproex for treatment of pediatric bipolar disorder. Current psychiatry reports. vol 13. issue 2. 2011-08-11. PMID:21249480. |
a head-to-head comparison of risperidone and divalproex for treatment of pediatric bipolar disorder. |
2011-08-11 |
2023-08-12 |
Not clear |
| Mani N Pavuluri, Alessandra M Passarotti, Lisa H Lu, Julie A Carbray, John A Sweene. Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder: fMRI outcomes. Psychiatry research. vol 193. issue 1. 2011-08-03. PMID:21592741. |
double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder: fmri outcomes. |
2011-08-03 |
2023-08-12 |
human |
| Rao Narasimha Malempati, David J Bond, Mauricio Kunz, Chaitanya Malemati, Amy Cheng, Lakshmi N Yatha. Long-term efficacy of risperidone long-acting injectable in bipolar disorder with psychotic features: a prospective study of 3-year outcomes. International clinical psychopharmacology. vol 26. issue 3. 2011-07-27. PMID:21372721. |
long-term efficacy of risperidone long-acting injectable in bipolar disorder with psychotic features: a prospective study of 3-year outcomes. |
2011-07-27 |
2023-08-12 |
Not clear |
| L Samalin, T Charpeaud, O Lorabi, Pm Llorc. Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection. Patient preference and adherence. vol 4. 2011-07-14. PMID:20859459. |
patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection. |
2011-07-14 |
2023-08-12 |
Not clear |
| L Samalin, T Charpeaud, O Lorabi, Pm Llorc. Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection. Patient preference and adherence. vol 4. 2011-07-14. PMID:20859459. |
in this context, the efficacy and tolerance of risperidone long-acting injection (rlai) for maintenance treatment in patients with bipolar disorder is assessed. |
2011-07-14 |
2023-08-12 |
Not clear |
| Mohit Trivedi, Denzil Pinto, A T Safeek. Risperidone mono - therapy as prophylaxis in bipolar affective disorders. Indian journal of psychiatry. vol 46. issue 3. 2011-07-14. PMID:21224912. |
risperidone has been found to be useful in the treatment of acute bipolar disorders. |
2011-07-14 |
2023-08-12 |
Not clear |
| Wissam El-Hage, Simon A Surguladz. Emerging treatments in the management of bipolar disorder - focus on risperidone long acting injection. Neuropsychiatric disease and treatment. vol 6. 2011-04-28. PMID:20856609. |
emerging treatments in the management of bipolar disorder - focus on risperidone long acting injection. |
2011-04-28 |
2023-08-12 |
Not clear |
| Edward Kim, Min You, Andrei Pikalov, Quynh Van-Tran, Yonghua Jin. One-year risk of psychiatric hospitalization and associated treatment costs in bipolar disorder treated with atypical antipsychotics: a retrospective claims database analysis. BMC psychiatry. vol 11. 2011-03-31. PMID:21214937. |
this study compared 1-year risk of psychiatric hospitalization and treatment costs in commercially insured patients with bipolar disorder, treated with aripiprazole, ziprasidone, olanzapine, quetiapine or risperidone. |
2011-03-31 |
2023-08-12 |
Not clear |
| Joseph Biederman, Paul Hammerness, Robert Doyle, Gagan Joshi, Megan Aleardi, Eric Mic. Risperidone treatment for ADHD in children and adolescents with bipolar disorder. Neuropsychiatric disease and treatment. vol 4. issue 1. 2011-02-22. PMID:18728799. |
risperidone treatment for adhd in children and adolescents with bipolar disorder. |
2011-02-22 |
2023-08-12 |
Not clear |
| Jeffrey R Bishop, Mani N Pavulur. Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia. Neuropsychiatric disease and treatment. vol 4. issue 1. 2011-02-22. PMID:18728804. |
review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia. |
2011-02-22 |
2023-08-12 |
Not clear |
| Jeffrey R Bishop, Mani N Pavulur. Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia. Neuropsychiatric disease and treatment. vol 4. issue 1. 2011-02-22. PMID:18728804. |
risperidone is a commonly used medication for the treatment of bipolar disorder and schizophrenia in children and adolescents. |
2011-02-22 |
2023-08-12 |
Not clear |
| Jeffrey R Bishop, Mani N Pavulur. Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia. Neuropsychiatric disease and treatment. vol 4. issue 1. 2011-02-22. PMID:18728804. |
studies to date indicate that risperidone is an effective treatment for positive and negative symptoms of schizophrenia and mania symptoms of bipolar disorder. |
2011-02-22 |
2023-08-12 |
Not clear |
| Jeffrey R Bishop, Mani N Pavulur. Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia. Neuropsychiatric disease and treatment. vol 4. issue 1. 2011-02-22. PMID:18728804. |
here we review published studies of risperidone for the treatment of bipolar disorder and schizophrenia in children and adolescents to provide practitioners with an overview of published data on the efficacy and safety of risperidone in these patient populations. |
2011-02-22 |
2023-08-12 |
Not clear |
| William V Bobo, Richard C Shelto. Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder. Expert review of neurotherapeutics. vol 10. issue 11. 2011-02-04. PMID:20977322. |
risperidone long-acting injectable (risperdal consta®) for maintenance treatment in patients with bipolar disorder. |
2011-02-04 |
2023-08-12 |
Not clear |
| Mani N Pavuluri, David B Henry, Robert L Findling, Stephanie Parnes, Julie A Carbray, Tahseen Mohammed, Philip G Janicak, John A Sweene. Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder. Bipolar disorders. vol 12. issue 6. 2010-12-27. PMID:20868458. |
double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder. |
2010-12-27 |
2023-08-12 |
Not clear |
| Diego Novick, Catherine Reed, Josep Maria Haro, Ana Gonzalez-Pinto, Elena Perrin, Jaume Aguado, Mauricio Tohe. Comparison of olanzapine and risperidone in the EMBLEM Study: translation of randomized controlled trial findings into clinical practice. International clinical psychopharmacology. vol 25. issue 5. 2010-12-02. PMID:20531011. |
data from the emblem study, a 2-year, prospective, observational study of health outcomes associated with acute treatment of patients experiencing a manic/mixed episode of bipolar disorder, was used to compare the effectiveness of olanzapine monotherapy versus risperidone monotherapy, and to investigate whether the treatment effects were similar to those reported in a 3-week, randomized controlled trial assessing the same treatments. |
2010-12-02 |
2023-08-12 |
Not clear |
| L Pérez Fernández, A Leache Alegría, L Ojer Pascua. [Pediatric bipolar disorder: on one case]. Anales del sistema sanitario de Navarra. vol 33. issue 1. 2010-10-28. PMID:20463777. |
during his hospital stay the patient was diagnosed as having bipolar disorder (in its maniac phase) and a long term treatment was initiated with a mind stabilizer (valproic acid) and antipsychotic (risperidone). |
2010-10-28 |
2023-08-12 |
Not clear |
| b' Marija Vuci\\xc4\\x87 Peitl, Vjekoslav Peitl, Tanja Grahovac, Eudard Pavlovi\\xc4\\x8. Galactorrhea - side effect of risperidone in combination with depakine chrono in a patient with bipolar disorder. Psychiatria Danubina. vol 22. issue 1. 2010-10-08. PMID:20305608.' |
galactorrhea - side effect of risperidone in combination with depakine chrono in a patient with bipolar disorder. |
2010-10-08 |
2023-08-12 |
Not clear |
| Gabrielle A Carlson, Michael Potegal, David Margulies, Joann Basile, Zinoviy Gutkovic. Liquid risperidone in the treatment of rages in psychiatrically hospitalized children with possible bipolar disorder. Bipolar disorders. vol 12. issue 2. 2010-09-22. PMID:20402713. |
liquid risperidone in the treatment of rages in psychiatrically hospitalized children with possible bipolar disorder. |
2010-09-22 |
2023-08-12 |
Not clear |